Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Core Insights - Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing new therapeutic pathways for obesity and metabolic health disorders [4] - The company is conducting a Phase 2a clinical trial for nimacimab, an antibody that inhibits CB1, and is also assessing its combination with a GLP-1R agonist [4] Investment Conferences - Skye will participate in several investment conferences, including: - Cantor Global Healthcare Conference on September 5, 2025 - H.C. Wainwright Global Investment Conference on September 8, 2025 - Morgan Stanley Global Healthcare Conference on September 10, 2025 [6] Medical/Scientific Conferences - Skye will also present at medical conferences, including: - Obesity Science & Innovation on September 16, 2025, with a keynote panel discussing pipeline priorities in obesity therapeutics - European Association for the Study of Diabetes Annual Meeting on September 19, 2025, presenting a study on the safety and tolerability of nimacimab in subjects with metabolic associated fatty liver disease [6]